(3S,4S)-Tofacitinib|CAS 1092578-47-6|DC Chemicals

Cas No.:	1092578-47-6
Chemical Name:	(3S,4S)-Tofacitinib
SMILES:	CN(C1=NC=NC2=C1C=CN2)[C@H]3[C@@H](C)CCN(C(CC#N)=O)C3
Formula:	C₁₆H₂₀N₆O
M.Wt:	312.37
Sotrage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month

Cat. No.	Product name	Field of application
DC47590	Ten01	Ten01 has 5.0 nM activity against JAK1 kinase.
DC47041	Lorpucitinib	Lorpucitinib is a Gut-Restricted JAK Inhibitor for the research of Inflammatory Bowel Disease.
DC47039	Itacnosertib	Itacnosertib (TP-0184) is both inhibitor to JAK2, ACVR1 (ALK2) and ALK5 as described in WO2014151871.
DC46857	Nezulcitinib	Nezulcitinib (TD-0903) is an inhaled and lung-selective pan-Janus kinase (JAK) inhibitor. Nezulcitinib can be used for the research of COVID-19 associated acute lung injury and impaired oxygenation.
DC46856	JAK2/FLT3-IN-1 TFA	JAK2/FLT3-IN-1 (TFA) is a potent and orally active dual JAK2/FLT3 inhibitor with IC50 values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. JAK2/FLT3-IN-1 (TFA) has anti-cancer activity.
DC46855	Deuruxolitinib	Deuruxolitinib (CTP-543), a deuterated Ruxolitinib, modulates the activity of JAK1/JAK2. Deuruxolitinib can be used for the research hair loss disorders (from patent WO2017192905A1, compound I).
DC44160	JAK2/FLT3-IN-1	JAK2/FLT3-IN-1 is a potent and orally active dual JAK2/FLT3 inhibitor with IC50 values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. JAK2/FLT3-IN-1 has anti-cancer activity.
DC42325	(3S,4S)-Tofacitinib	(3S,4S)-Tofacitinib is the less active S-enantiomer of Tofacitinib. Tofacitinib inhibits JAK3 with IC50 of 1 nM.
DC42324	JAK2-IN-7	JAK2-IN-7 is a selective JAK2 with IC50s of 3, 11.7, and 41 nM for JAK2, SET-2, and Ba/F3V617F cells. JAK2-IN-7 possesses >14-fold selectivity over JAK1, JAK3, FLT3. JAK2-IN-7 stimulates cell cycle arrest in the G0/G1 phase and induces tumor cellapoptosis. Antitumor activities.
DC41406	Coumermycin A1	Coumermycin A1 is a JAK2 signal activator. Coumermycin A1 inhibits DNA Gyrase which thereby inhibits cell division in bacteria.